Skip to search formSkip to main contentSkip to account menu

MART-1 Antigen (vaccine component)

Known as: MelanA, Melan A, MART-1 Antigen 
A protein found on normal melanocytes (cells that make the pigment melanin) in the skin and in the retina. It is also found on most melanomas… 
National Institutes of Health

Related topics

Related topics

4 relations
Anti-MART-1 TCR Retroviral Vector-Transduced Autologous TILMLANA geneNCIt Antineoplastic Agent Terminology

Broader (1)

MART-1 Antigen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Alum with Interleukin-12 Augments Immunity to a Melanoma Peptide Vaccine: Correlation with Time to Relapse in Patients with Resected High-Risk Disease
Purpose: We attempted to augment immunity to melanoma antigens using interleukin-12 (IL-12) with aluminum hydroxide (alum) for… 
Highly Cited
2005
Highly Cited
2005
Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells.
Down-regulation of immune responses by regulatory T (Treg) cells is an important mechanism involved in the induction of tolerance… 
Highly Cited
2001
Highly Cited
2001
Mature Dendritic Cells Prime Functionally Superior Melan-A-Specific CD8+ Lymphocytes as Compared with Nonprofessional APC1
Priming of melan-A26/27–35-specific CTL occurs only in a fraction of late stage melanoma patients, whereas during the early… 
Highly Cited
2001
Highly Cited
2001
Comprehensive analysis of the frequency of recognition of melanoma‐associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy
Fifty‐nine tumor‐infiltrating lymphocyte (TIL) cultures established from melanoma‐invaded lymph nodes were screened for… 
Highly Cited
1999
Highly Cited
1999
MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases.
PURPOSE Polymerase chain reaction (PCR) with tyrosinase and with MART-1 permits detection of small numbers of circulating… 
Highly Cited
1998
Highly Cited
1998
Overlapping peptides of melanocyte differentiation antigen melan‐A/MART‐1 recognized by autologous cytolytic T lymphocytes in association with HLA‐B45.1 and HLA‐A2.1
From the peripheral blood lymphocytes (PBLs) of melanoma patient SK29(AV) we have previously isolated 2 independent cytolytic T… 
Highly Cited
1998
Highly Cited
1998
Circulating MELAN‐A/MART‐1 specific cytolytic T lymphocyte precursors in HLA‐A2+ melanoma patients have a memory phenotype
Melan‐A/MART‐1 is a melanoma differentiation antigen that is recognized by a high proportion of cytolytic T lymphocyte (CTL… 
Highly Cited
1997
Highly Cited
1997
Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ‐ELISPOT assay
We have established a sensitive ELISPOT assay measuring interferon γ (IFN γ) release on a single‐cell basis to detect influenza… 
Highly Cited
1996
Highly Cited
1996
Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
To determine whether HLA-A21 restricted melanoma Ags exist that are not expressed on normal melanocytes, a panel of 478 T cell… 
Highly Cited
1995
Highly Cited
1995
Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
To determine whether T-cell-receptor (TCR) usage by T cells recognizing a defined human tumor antigen in the context of the same… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)